Pankti Reid, MD, MPH, rheumatologist, assistant professor ​of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs).

Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagnostic tools and identification of efficacious therapies beyond steroids, is needed.

Systemic steroids, which are currently the standard of care for managing irAEs, are associated with significant toxicities of their own, explains Reid. Additionally, managing irAEs often calls for high-dose steroids given over a long period of time.

As such, developing steroid-sparing regimens is necessary to reduce the potential impact of treatment for irAEs, concludes Reid.

Videos

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.  



Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs 

Pankti Reid, MD, MPH, rheumatologist, assistant professor ​of medicine, University of Chicago Medicine, discusses ​assessing immune-related adverse effects (irAEs) patients with cancer.

Patient history has always been a key driver in how questions ​regarding irAEs are addressed, says Reid. Notably, some irAEs present early in the course of treatment, while others take longer to develop​, adds Reid.

Low-grade toxicities are usually quicker to treat, especially with medications such as topical steroids, ​says Reid. While this may clue into the potential for higher-grade toxicities, prospective research is still needed to study this potential.

Ultimately, becoming familiar with a patient’s history of irAEs is of paramount importance when treating patients with checkpoint inhibitors, Reid concludes.

Pankti Reid, MD, MPH, discusses ​assessing immune-related adverse effects (irAEs) patients with cancer.

Pankti Reid, MD, MPH

Articles

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

Dr. Reid on Assessing irAEs in Patients With Cancer